Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction Not Responding to Approved Oral or Intracorporeal Vasoactive Treatments.
Overview
- Phase
- Phase 2
- Intervention
- Botulinum toxin A
- Conditions
- Erectile Dysfunction With Diabetes Mellitus
- Sponsor
- Aswan University Hospital
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Treatment.
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Study is aiming to evaluate safety, efficacy and durability of intracavernosal injection (ICI) of Botulinum toxin A plus oral tadalafil in controlled diabetic men with refractory Erectile Dysfunction.
Detailed Description
Total of (32) male patients will be included in this study and will be recruited from the Andrology, Sexology \& STDs outpatient clinics- Faculty of medicine -Cairo and Aswan Universities. All those patients are complaining of erectile dysfunction Unresponsive to Approved Pharmacological Treatments. Each patient will have an informed consent obtained prior to conducting the study. All patients will be subjected to the following: * History taking. * Clinical examination (general and local genital examination). * International Index of Erectile Function (IIEF-5) before and after treatment (Rosen et al., 2002). * Erection Hardness Score (EHS) before and after treatment (Mulhall et al., 2006). * Global assessment questionnaire after treatment (Giuliano et al., 2007). * All patients will be examined by Duplex Doppler ultrasonography in the basal condition and after the induction of penile erection with the assistance of an intracavernous injection of alprostadil 20 μg/mL. * All patients will receive single dose of ICI of 100u of (BTXA) combined with 5mg oral Tadalafil once daily for 3 months. * The subjects will be re-examined and International Index of Erectile Function (IIEF-5), Erection Hardness Score (EHS)and penile color Doppler ultrasound with PGE-1 injection will be done at 6 and 12 weeks from the start of therapy in addition to Global assessment questionnaire will be done at 12 weeks from the start of therapy \* Procedure * The patients will lied down in supine position. After cleansing the skin with alcohol, intracavernosal injection of single dose 100U (BTX-A) diluted in isotonic saline 2cm proximal to coronal margin at right and left sides will be performed and the injection site will be pressed directly for two minutes. To prevent systemic toxicity, a veno-occlusive ring will be used at the base of the penis at the time of injection and will be kept in place for 15 minutes after injection.
Investigators
El Hassan Mohsen Mansour Mahmoud
Assistant lecturer
Aswan University Hospital
Eligibility Criteria
Inclusion Criteria
- •Adult controlled diabetic married men who proved to be vasculogenic ED by Penile Duplex.
- •Men who had shown an insufficient response for at least 3 months to the registered PDE5-Is at the highest approved dose, either on-demand or daily, or to PGE1 ICIs.
- •Severe erectile dysfunction (erection hardness score ≤ E3 after intracavernosal injection of PGE-1).
Exclusion Criteria
- •Men who had cardiovascular disease interfering with sexual activity.
- •Men with history of an unstable psychiatric conditions
- •Presence of penile anatomical abnormalities that would significantly impair erectile function.
- •History of spinal or pelvic radical surgery.
Arms & Interventions
Group 1
32 patients will be injected single intracavernosal injection of 100 unit of Botulinum toxin A accompained by oral daily tadalafil 5 mg for 3 months.
Intervention: Botulinum toxin A
Group 1
32 patients will be injected single intracavernosal injection of 100 unit of Botulinum toxin A accompained by oral daily tadalafil 5 mg for 3 months.
Intervention: Tadalafil 5mg
Outcomes
Primary Outcomes
Treatment.
Time Frame: 3 months
The primary outcome is to assess the effect of single intra-cavernosal injection of 100 unit of botulinum-A toxin plus daily intake of 5mg oral tadalafil in 32 adult diabetic patients with erectile dysfunction to detect its effect on on the erectile function status by reporting changes in IIEF and penile doppler parameters.
Secondary Outcomes
- Secondary adverse events of the drug.(3months)